Research programme: connective tissue regeneration therapies - Bio3 ResearchAlternative Names: CTR-1; CTR-2; CTR-3; CTR-4
Latest Information Update: 04 Feb 2011
At a glance
- Originator Bio3 Research
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Bone disorders; Cartilage disorders; Musculoskeletal disorders; Wounds
Most Recent Events
- 04 Feb 2011 Preclinical development is ongoing in Italy
- 12 Feb 2007 Preclinical development is ongoing
- 16 Aug 2005 Preclinical trials in Wounds in Italy (unspecified route)